Has Elysse Tom, MD received payments from drug or device companies?

Yes. Drug and device makers reported $4,646 in general payments to Elysse Tom, MD across 51 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Elysse Tom, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Elysse Tom, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Elysse Tom, MD

Ophthalmology · Honolulu, HINPI 1659806594

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 51 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations.

$4,646in general payments, 2019–2025

Across 51 payments — averaging $91.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Alcon$923
Genentech USA, Inc.$775
Sight Sciences, Inc.$593
Regeneron Healthcare Solutions, Inc.$545
Dompe US, Inc.$371
Astellas Pharma Global Development$252
plus $1K from 9 others

$15,000in research payments, 2019–2025

Across 1 payment — averaging $15,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Genentech, Inc.$15K

What the payments were for

Food & beverage$4,646100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Alcon	5	$923
Genentech USA, Inc.	15	$775
Sight Sciences, Inc.	5	$593
Regeneron Healthcare Solutions, Inc.	7	$545
Dompe US, Inc.	3	$371
Astellas Pharma Global Development	2	$252
Mallinckrodt Hospital Products Inc.	2	$240
Astellas Pharma US Inc	2	$203
Regeneron	2	$136
Johnson & Johnson	1	$122
Oyster Point Pharma, Inc.	1	$121
Apellis Pharmaceuticals, Inc.	1	$112
Biogen	2	$102
Bausch & Lomb Americas Inc.	2	$98
Beaver-visitec International, Inc.	1	$52

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,646 in reported general payments places this provider in the 65th percentile of 120 ophthalmology providers in Hawaii.

See all ophthalmology providers in Hawaii →

Medicare billing

Part B allowed, 2024

$1,051,454

Medicare patients

523

Services billed

11,301

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Prednisolone Acetate	133	$8,114
ProlensaBromfenac Sodium	13	$4,531
Bromfenac Sodium	17	$2,784
Ofloxacin	91	$1,114
Ketorolac Tromethamine	25	$631
Brimonidine Tartrate	17	$592
Atropine Sulfate	12	$589
MoxifloxacinMoxifloxacin Hcl	16	$533
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat	33	$405
Timolol Maleate	12	$80

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Honolulu

Neda NikpoorHonolulu$293K
Carlton YuenHonolulu$175K
Alan FaulknerHonolulu$135K
Michael BennettHonolulu$108K
Jeffrey PetersonHonolulu$77K
Rupa WongHonolulu$72K
Jon PortisHonolulu$20K
Tyrie JenkinsHonolulu$19K
John OlkowskiHonolulu$15K
Claudia HootenHonolulu$14K

See the full list for Hawaii →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →